Aclaris Therapeutics (NASDAQ: ACRS) sells 5.7M shares to raise $20M

Rhea-AI Filing Summary

Aclaris Therapeutics reported that on March 10, 2026 it sold 5.7 million shares of its common stock, generating $20.0 million in aggregate gross proceeds. The sale was made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.

The agents informed the company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure is furnished under Regulation FD and is not treated as filed for liability purposes under the Exchange Act.

Insights

Biopharma capital markets analyst

Aclaris raised $20M through an at-the-market equity sale.

Aclaris Therapeutics completed the sale of 5.7 million common shares for gross proceeds of $20.0 million under its sales agreement with Leerink Partners and Cantor Fitzgerald. This looks like a follow-on use of an existing at-the-market program rather than a new financing structure.

The buyers—Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP—are institutional investors, indicating demand from specialized healthcare funds. The filing does not detail net proceeds or specific use of funds, so the direct financial impact depends on the company’s existing cash position and burn rate.

The transaction is presented as a Regulation FD disclosure, emphasizing transparency around the completed share sale on March 10, 2026. Subsequent periodic reports may provide more context on how the additional $20.0 million supports operations or clinical and development plans.

0001557746false00015577462026-03-102026-03-10

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): March 10, 2026

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware	​	001-37581	​	46-0571712
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: 

​

Title of Each Class:	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of Each Exchange on which Registered
Common Stock, $0.00001 par value		ACRS		The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 7.01 Regulation FD Disclosure.

On March 10, 2026, Aclaris Therapeutics, Inc. (the “Company”) sold 5.7 million shares of its common stock, for aggregate gross proceeds of $20.0 million pursuant to the Company’s amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. (the “Agents”) dated February 27, 2025. The Agents have informed the Company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	ACLARIS THERAPEUTICS, INC.
​	​	​
​	By:	/s/ Kevin Balthaser
Date: March 11, 2026	​	Kevin Balthaser
​	​	Chief Financial Officer

​

​

3

FAQ

What capital did Aclaris Therapeutics (ACRS) raise in this transaction?

Aclaris Therapeutics raised $20.0 million in aggregate gross proceeds by selling 5.7 million shares of common stock. The sale occurred on March 10, 2026 under its amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald.

How many shares did Aclaris Therapeutics (ACRS) issue on March 10, 2026?

On March 10, 2026, Aclaris Therapeutics issued 5.7 million shares of its common stock. These shares were sold through its sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., generating $20.0 million in gross proceeds.

Who purchased the newly issued Aclaris Therapeutics (ACRS) shares?

The newly issued Aclaris Therapeutics shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. These institutional investors acquired the 5.7 million common shares sold under the company’s amended and restated sales agreement.

What agreement did Aclaris Therapeutics (ACRS) use for the $20 million share sale?

Aclaris used its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. dated February 27, 2025. Under this agreement, the company sold 5.7 million common shares for $20.0 million in gross proceeds.

Is the Aclaris Therapeutics (ACRS) $20 million share sale information considered filed with the SEC?

No, the information is furnished, not filed, under Regulation FD. It is not deemed filed for Section 18 liability under the Exchange Act and is only incorporated into other filings if specifically referenced by the company.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 EX-101.SCH 2.6 KB
• EX-101 EX-101.LAB 15.5 KB
• EX-101 EX-101.PRE 10.0 KB